Zoetis Stock Forecast, Price & News

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zoetis stock.
View analyst ratings for Zoetis or view top-rated stocks.

Wall Street analysts have given Zoetis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zoetis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Zoetis saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,690,000 shares, an increase of 29.6% from the March 15th total of 3,620,000 shares. Based on an average trading volume of 2,100,000 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.0% of the company's stock are sold short.
View Zoetis' Short Interest.

Zoetis is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Zoetis.

Zoetis will be holding an earnings conference call on Thursday, May 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Zoetis Inc. (NYSE:ZTS) posted its earnings results on Tuesday, February, 16th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.86 by $0.05. The business earned $1.81 billion during the quarter, compared to analysts' expectations of $1.73 billion. Zoetis had a net margin of 25.50% and a trailing twelve-month return on equity of 63.89%. During the same quarter in the previous year, the company posted $0.92 earnings per share.
View Zoetis' earnings history.

Zoetis' stock was trading at $130.27 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ZTS shares have increased by 29.0% and is now trading at $168.10.
View which stocks have been most impacted by COVID-19.

Zoetis announced a quarterly dividend on Wednesday, February 10th. Investors of record on Wednesday, April 21st will be given a dividend of $0.25 per share on Tuesday, June 1st. This represents a $1.00 annualized dividend and a dividend yield of 0.59%. The ex-dividend date is Tuesday, April 20th.
View Zoetis' dividend history.

Zoetis pays an annual dividend of $1.00 per share and currently has a dividend yield of 0.60%. Zoetis does not yet have a strock track record of dividend growth. The dividend payout ratio of Zoetis is 27.47%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Zoetis will have a dividend payout ratio of 24.27% next year. This indicates that Zoetis will be able to sustain or increase its dividend.
View Zoetis' dividend history.

Zoetis issued an update on its FY 2021 Pre-Market earnings guidance on Tuesday, February, 16th. The company provided earnings per share guidance of 4.36-4.46 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.26. The company issued revenue guidance of $7.4-7.55 billion, compared to the consensus revenue estimate of $7.11 billion.

15 brokerages have issued 12 month target prices for Zoetis' stock. Their forecasts range from $126.00 to $203.00. On average, they expect Zoetis' stock price to reach $170.08 in the next year. This suggests a possible upside of 1.2% from the stock's current price.
View analysts' price targets for Zoetis or view top-rated stocks among Wall Street analysts.

50 employees have rated Zoetis CEO Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among Zoetis' employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

Some companies that are related to Zoetis include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of ZTS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Zoetis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Chicago Capital LLC (0.06%), FDx Advisors Inc. (0.06%), AMI Asset Management Corp (0.05%), DnB Asset Management AS (0.05%), Gofen & Glossberg LLC IL (0.05%) and Royal London Asset Management Ltd. (0.04%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends for Zoetis.

ZTS stock was sold by a variety of institutional investors in the last quarter, including FDx Advisors Inc., AMI Asset Management Corp, Hexavest Inc., DnB Asset Management AS, Calamos Advisors LLC, Retirement Systems of Alabama, Union Bancaire Privee Asset Management LLC, and TrimTabs Asset Management LLC. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Roxanne Lagano, and Willie M Reed.
View insider buying and selling activity for Zoetis or view top insider-selling stocks.

ZTS stock was acquired by a variety of institutional investors in the last quarter, including UNIVEST FINANCIAL Corp, FDx Advisors Inc., Everence Capital Management Inc., Renaissance Investment Group LLC, CX Institutional, Farmers & Merchants Investments Inc., Baldwin Brothers Inc. MA, and Harbour Capital Advisors LLC.
View insider buying and selling activity for Zoetis or or view top insider-buying stocks.

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZTS stock can currently be purchased for approximately $168.10.

Zoetis has a market capitalization of $79.85 billion and generates $6.26 billion in revenue each year. The company earns $1.50 billion in net income (profit) each year or $3.64 on an earnings per share basis.

Zoetis employs 11,300 workers across the globe.

The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Holding Limited, Abaxis Europe GmbH, Abaxis Holding GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma (Bermuda) LLC, Alpharma (Luxembourg) S.A.R.L. y Compania Limitada, Alpharma (Luxembourg) S.àr.l., Alpharma Animal Health (Hong Kong) Co. Limited, Alpharma Animal Health Company, Alpharma Euro Holdings LLC, Alpharma Holdings (Barbados) SRL, Alpharma LLC, Alpharma do Brasil Ltda., Bovigen, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Mikjan Corporation, NVIP Pty Ltd, Nexvet, Nexvet Australia Pty Ltd, Nordic Fish Tech AB, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PHARMAQ LTD, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS Technika SpA, Pharmaq Analytiq AS, Pharmaq CA Panama Inc., Pharmaq Fishteq AS, Pharmaq Holding AS, Pharmaq Settvac AS, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Platinum Performance, Platinum Performance Inc., Platinum Performance Nutrition Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics LLC, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis (Thailand) Limited, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark Aps, Zoetis Deutschland GmbH, Zoetis Egypt Import LLC, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management (Shanghai) Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis International Services, Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Lab Holdings LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa (Pty) Ltd., Zoetis Spain S.L., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Taiwan Limited, Zoetis Treasury Center BVBA, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..

Zoetis was founded in 2012.

The official website for Zoetis is www.zoetis.com.

Zoetis is headquartered at 10 Sylvan Way, Parsippany NJ, 07054.

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]